| # | Trial Name/ID | Status | Phase | General RA Method | Sample Size (final/planned) | Number of Arms | Outcome | Condition | Primary Endpoint | Notes | DOI | Year of Publication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ABT-089 | completed | II | BRAR | 337 | 7 | Ordinal | Mild Alzheimer | Alzheimer’s Disease Assessment Scale, cognition subscale (ADAS-Cog) total score | stoped early for futility | [DOI link](https://doi.org/10.1097/WAD.0000000000000093) | 2015 |
| 2 | ADORE | completed | III | BRAR | 1100 | 2 | Binary | Preterm birth | earliest preterm birth (<34 weeks) (ePTB) | | [DOI link 1](https://doi.org/10.1186/s12884-017-1244-5), [DOI link 2](https://doi.org/10.1016/j.eclinm.2021.100905), [DOI link 3](https://doi.org/10.1080/10543406.2022.2148161) | 2017, 2021, 2022 |
| 3 | Adverse Karyotype Acute Myeloid Leukemia | completed | | BRAR | 34 | 3 | Binary | Leukemia | Complete remission without nonhematologic grade 4 toxicity by 50 days | | [DOI link](https://doi.org/10.1200/jco.2003.11.016) | 2003 |
| 4 | APPEX-19 / NCT04344587 | Completed | N/A | BRAR | 293 | 2 | Binary | COVID-19 | Composite of respiratory deterioration or ICU transfer | | [DOI link](https://doi.org/10.1016/j.chest.2022.05.009) | 2020 |
| 5 | ARREST / NCT03880565 | completed | II | BRAR | 30/176 | 2 | Survival | refractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest | Number of patients who survived to hospital discharge | Terminated early posterior probability of ECMO superiority exceeded the prespecified monitoring boundary. RAR never employed because first 30 patients randomised using ER. | [DOI link 1](https://doi.org/10.1016/j.ahj.2020.07.006), [DOI link 2](https://doi.org/10.1016%2FS0140-6736(20)32338-2) | 2020, 2020 |
| 6 | ASTIN | completed | II | BRAR | 966 | 16 | Ordinal | acute ischemic stroke | Change from baseline to day 90 on the Scandinavian Stroke Scale | | [DOI link](https://doi.org/10.1161/01.STR.0000092527.33910.89) | 2003 |
| 7 | ATTACC / NCT04372589 | completed | II/III | BRAR | 1200/3000 | 2 | Ordinal Categorical | Covid-19 | Three possible outcomes based on the worst status of each patient through day 30 | | [DOI link](https://doi.org/10.1177/1740774520943846) | 2020 |
| 8 | AuTOMATIC / ACTRN12618000789268 | Completed | - | BRAR | Target 10000 | 13 | Binary | Childhood immunisation coverage | Vaccination status | Initial randomisation ratios will be equal across the 12 active arms with scheduled analyses using a Bayesian response adaptive algorithm | [DOI link](https://doi.org/10.1186/s13063-023-07097-3) | 2022 |
| 9 | AVERT DOSE / ACTRN12619000557134 | Recruiting | III | | 2700 | 4 | Binary | Stroke | No or little disability assessed using modified Rankin Score (mRS) of 0-2 at 3 months post stroke | | [DOI link](https://doi.org/10.1177/17474930221142207) | 2019 |
| 10 | AWARD-5 / NCT00734474 | completed | III | BRAR | 1202/1566 | 9 | ordinal | type 2 diabetes | Clinical utility index (CUI) with possible values from 0 to 6 | | [DOI link](https://doi.org/10.1111/dom.12305) | 2014 |
| 11 | AZURE / NCT01391338 | Completed | II | BRAR | 239 | 6 | Continuous | Chronic Pelvic Pain Syndrome | Change from baseline in the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), total score at 12 weeks | | [DOI link](https://doi.org/10.1002/bimj.201700210) | 2011 |
| 12 | BATTLE / NCT00409968, NCT00411671, NCT00411632, NCT00410059, NCT00410189 | completed | II | | 255 | 4 | Binary | lung cancer | 8-week disease control rate (DCR) | | [DOI link](https://doi.org/10.1158/2159-8274.CD-10-0010) | 2011 |
| 13 | BATTLE-2 | completed | II | - | 186/200 | 4 | Binary | lung cancer | 8-week disease control rate (DCR) | Umbrella Trial incl. Biomarkers | [DOI link](https://doi.org/10.1200/JCO.2015.66.0084) | 2016 |
| 14 | DAWN / NCT03201419 | Completed | II | BRAR | 302 | 9 | Continuous | Nocturia | Change from baseline in aggregated mean number of nocturnal voids during 12 weeks of treatment | | [DOI link](https://doi.org/10.1002/bimj.201700210) | 2017 |
| 15 | dexFEM / NCT01769820 | Completed | - | BRAR | 107 | 2 | Continuous | HMB | change from baseline in laboratory-assayed MBL | five pre-planned interim analyses used primary outcome data to adjust randomisation probabilities to favour doses providing most dose-response information | [DOI link](https://doi.org/10.1016/j.ebiom.2021.103434) | 2014, 2017 |
| 16 | ECMO / NCT03201419 | Completed | II | RPTW | 12 | 2 | Binary | Respiratory failure | Death, lung recovery, or survival | | [DOI link](https://doi.org/10.1542/peds.76.4.479) | 1985 |
| 17 | EMPACT / ACTRN12623001004651 | Recruiting | II | BRAR | 140 | 4 | Continuous | Depression | Scores on the Hamilton Depression Scale (HAM-D) | | [DOI link](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12623001004651) | 2023 |
| 18 | endTB | completed | III | BRAR | 750 | 6 | Binary | tuberculosis | Treatment success at 73 weeks after randomisation | BRAR for non-inferiority. Extensive simulation results. | [DOI link 1](https://doi.org/10.1177/1740774516665090) [DOI link 2](https://link.springer.com/article/10.1186/s13063-021-05491-3) [DOI link 3](https://nejm.org/doi/full/10.1056/NEJMoa2400327) | 2016, 2021 |
| 19 | ESETT / NCT01960075 | completed | III | BRAR | 478/795 | 3 | Binary | Benzodiazepine-refractory status epilepticus | Clinical cessation of status epilepticus | Burn-In of 300 patients total | [DOI link 1](https://doi.org/10.1111/epi.12288) [DOI link 2](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30611-5/fulltext) | 2013, 2020 |
| 20 | Fluoxetine | completed | | RPTW | 89 | 2 | Ordinal | Depressive Disorder | total of the first 17 items of the Hamilton Depression Scale (HAMD17) | | [DOI Link](https://doi.org/10.1080/01621459.1994.10476810) | 1993 |
| 21 | GBM AGILE / NCT03970447 | recruiting | seamless phase II/III | BRAR | 1030/550 | Multi-arm | Binary | Glioblastoma | Overall survival | | [DOI link](https://doi.org/10.1158/1078-0432.CCR-17-0764) | 2018 |
| 22 | Gemcitabine for Metastatic Soft Tissue Sarcomas / NCT00142571 | completed | II | BRAR | 122 | 2 | | Metastatic Soft Tissue Sarcomas | tumor response (complete or partial response or stable disease lasting at least 24 weeks) | | [DOI Link](https://doi.org/10.1200/JCO.2006.10.4117) | 2007 |
| 23 | Ghrelin Agonist TZP-101 | completed | II b | | 236 | 8 | Time-to-Event | Postoperative Ileus After Partial Colectomy | Time to first bowel movement | | [DOI link](https://doi.org/10.1007%2FDCR.0b013e3181b54166) | 2010 |
| 24 | HOBIT / NCT02407028 | Recruiting | II | BRAR | 200 | 8 | Binary | Traumatic brain injury | Glasgow Outcome Scale Extended (GOS-E) | | [DOI link](https://doi.org/10.1002/pst.1755) | 2018 |
| 25 | ICECAP / NCT04217551 | recruiting | not applicable | BRAR | 1800 | 20 | Ordinal | Neuroprotection after cardiac arrest | weighted modified Rankin Scale (mRS) | mRS is a measure of neurologic disability | [DOI Link](https://doi.org/10.21203/rs.3.rs-4033108/v1) | 2024 |
| 26 | INCEPT / NCT06667999 | Recruiting | IV | BRAR | Target 10.000 | interventions grouped in domains, continuously being added | Binary/ordinal (depending on domain) | Adults acutely admitted to the intensive care unit | Different primary outcome per domain | | [DOI link](https://doi.org/10.1111/aas.70023) | 2025 |
| 27 | INSIGhT / NCT02977780 | Completed | II | BRAR | 237 | 3 | Time-to-event | Newly diagnosed glioblastoma | Overall survival | Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data | [DOI link](https://doi.org/10.1200/JCO.23.00493) | 2023 |
| 28 | Insulin sliding scale vs weight-based regimen | | | BRAR | | 3 | Continuous | | Hospital length of stay | Tuned BRAR with Bayesian stopping rule | [DOI link](https://doi.org/10.1177%2F1740774511398368) | 2011 |
| 29 | I-SPY 2 | completed | II & III | BRAR | 272 | Multi-arm (many treatment combinations) | | Breast Cancer | Pathologic complete response (pCR) | Biomarkers, Dropping arms when Bayesian probability below a threshold | [DOI link 1](https://doi.org/10.1038/clpt.2009.68), [DOI link 2](https://doi.org/10.1056/NEJMoa1513749), [DOI link 3](https://doi.org/10.1056/NEJMoa1513750) | 2009, 2016, 2016 |
| 30 | KENDO / NCT03227328 | Completed | II | DBCD | 49 | 2 | Time-to-event | Breast cancer | Time from randomisation until first disease progression or death | | [DOI link](https://doi.org/10.1093/oncolo/oyad337) | 2017 |
| 31 | Ketamine in LL-TRD | completed | II | BRAR | 33 | 5 | | late-life treatment-resistant depression | Treatment response 50% improvement on depression rating scale | | [DOI link 1](https://doi.org/10.1016/j.conctc.2019.100432), [DOI link 2](https://doi.org/10.1038/s41386-021-01242-9) | 2019, 2021 |
| 32 | Ketodex / NCT0419525 | - | - | BRAR | 410 | 2 | Binary | simple upper limb fracture or dislocation that requires sedation | adequate sedation as measured using the Paediatric Sedation State Scale | participants will be randomised to intranasal Ketodex or intravenous ketamine with a 3:2 allocation ratio. Participants receiving intranasal Ketodex will be further adaptively randomised to three alternative combinations where the randomisation ratio is proportional to the posterior probability that a combination is optimal in terms of providing adequate sedation | [DOI link](https://doi.org/10.1136/bmjopen-2020-041319) | 2020 |
| 33 | LaRRC / 2013-001203-36 | Recruiting | II | BRAR | 80 | 2 | Binary | Rectal cancer | Pathologic complete remission | | [DOI link](https://doi.org/10.1186/s13063-016-1583-y) | 2013 |
| 34 | Leborexant / NCT01995838 | completed | II | BRAR | 291/300 | 7 | | insomnia | Utility function integrating sleep efficiency and safety | | [DOI link](https://doi.org/10.5664/jcsm.6800) | 2017 |
| 35 | Low-Dose DecitabineWith or Without Valproic Acid in Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia | Completed | II | BRAR | 149 | 2 | Binary | Myelodysplastic syndrome and acute myelogenous leukemia | Survival status | | [DOI link](https://doi.org/10.1002/cncr.29085) | 2015 |
| 36 | M-FIT / ACTRN12620000408987 | Recruiting | N/A | BRAR | 400 | 4 | Continuous | Kidney disease | Fatigue as measured by Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire | | [DOI link](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000408987) | 2020 |
| 37 | MOTIVATE-C / ACTRN12623000024640 | recruiting | not applicable | BRAR | 1300 | 21 | | Hepatitis-C | Initiation of Direct-acting antiviral (DAA) therapy for hepatitis C infection | | [DOI Link](https://doi.org/10.1186/s13063-024-08212-8) | 2024 |
| 38 | NCT00500578 | Completed | IV | BRAR | 51 | 2 | Binary | Hematological malignancies | Treatment failure defined as progression to pneumonia within 7 days of initial treatment with aerosolized ribavirin | | [DOI link](https://doi.org/10.1093/infdis/jis516) | 2003 |
| 39 | NCT00915005 | Completed | II | BRAR | 149 | 4 | Time-to-event | Lung cancer | Time to development of CTCAE v3.0 grade > 3 TRP | | [DOI link](https://doi.org/10.1200/JCO.2017.74.0720) | 2009 |
| 40 | NCT01000051 | Completed | II | BRAR | 63 | 2 | Binary | Thrombocytopenia | Target platelet count of >= 50,000/mL at day 57 | | [DOI link](https://doi.org/10.1016/j.jtct.2021.02.004) | 2010 |
| 41 | NCT01289457 | Completed | II | BRAR | 182 | 2 | Time-to-event | Leukemia | Event-free survival | | [DOI link](https://doi.org/10.1002/cncr.30883) | 2011 |
| 42 | NCT01613586 | Completed | II | BRAR | 286 | 4 | Continuous | Urinary disorder | Change from baseline in Mean Daily Pain (MDP) at 12 weeks | | [DOI link](https://clinicaltrials.gov/study/NCT01613586) | 2012 |
| 43 | NCT01767311 | Completed | II | BRAR | 854 | 6 | Continuous | Alzheimer’s disease | Change from baseline in the Alzheimer's Disease Composite Score (ADCOMS) at 12 months | | [DOI link](https://doi.org/10.1186/s13195-022-00995-9) | 2012 |
| 44 | NCT01786343 | Completed | II | BRAR | 71 | 2 | Binary | Leukemia | Response of Complete Response (CR) + Partial Remission (PR) + Complete Remission with incomplete recovery (CRi) + Clinical Benefit | | [DOI link](https://doi.org/10.1016/S2352-3026(18)30182-0) | 2013 |
| 45 | NCT02045797 | Completed | II | BRAR | 122 | 3 | Binary | Infection | Composite of efficacy and safety which consisted of the early cure rate and the withdrawal rate due to drug-related adverse events and utilized a clinical utility index for dose selection | | [DOI link](httpspro://doi.org/10.1128/AAC.02095-16) | 2014 |
| 46 | NCT02110069 | Terminated | II | | 4 | 2 | Binary | Vascular tumors | Change in hematologic parameters | Did not end up using RAR as terminated early due to rare condition | [DOI link](https://clinicaltrials.gov/study/NCT02110069) | 2017 |
| 47 | NCT02380625 | Terminated | I/II | BRAR | 400 | 4 | Binary | Ebola | Death by day 14 | Did not start due to decline in condition | [DOI link](https://doi.org/10.1177/1740774515621721) | 2015 |
| 48 | NCT03227224 | Completed | II | Adapted according to the dose-response curve | 287 | 3 | Continous | Depression | Change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score | | [DOI link](https://doi.org/10.1093/ijnp/pyab050) | 2017 |
| 49 | NCT04058028 | Completed | IIb | BRAR | 244 | 4 | Binary | Active Systemic Lupus Erythematosu | Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52 | Response Adaptive Randomization to allocate more patients to more efficacious doses and fewer patients to less efficacious doses | [DOI link](https://doi.org/10.3899/jrheum.2025-0390.PT014) | 2025 |
| 50 | NUDGE-EHR | Ongoing | N/A | Pick-the-winner | 201 (stage 1) | 16 | Binary | Inappropriate prescribing in ≥ 65 years | “reduction” in inappropriate prescribing | Adaptive randomized pragmatic trial. Two-stage “pick-the-winner” design. Intervention: EHR Tools with behavioral principles. Control: usual care. | [Link](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003658) | 2021 |
| 51 | OPTIMISE-C19 / NCT04790786 | Terminated | IV | BRAR | 4571 | 4 | Ordinal | COVID-19 | Days alive and free from hospitalisation | | [DOI link](https://doi.org/10.1186/s13063-021-05316-3) | 2021 |
| 52 | PAIN-CONTRoLS / NCT02260388 | completed | III | BRAR | 402 | 4 | Discrete | cryptogenic sensory polyneuropathy (CSPN) | Combination of two endpoints: at least 50% pain reduction in Likert scale AND observed percentage of patients who quit | Burn-in of 20 patients per arm | [DOI link 1](https://doi.org/10.1186/s13063-016-1544-5), [DOI link 2](https://doi.org/10.1001/jamaneurol.2020.2590), [DOI link 3](https://doi.org/10.1016/j.conctc.2023.101220) | 2016, 2020, 2023 |
| 53 | PRINCIPLE / ISRCTN86534580 | Completed | III | BRAR | 11768 | 7 | Binary & time-to-event | COVID-19 | Hospitalisation and/or death & time taken to self-reported recovery | | [DOI link](https://www.principletrial.org/) | 2020 |
| 54 | ProBio / NCT03903835 | Recruiting | III | BRAR | 750 | Ongoing platform | Time-to-event | Prostate cancer | Progression free survival | | [DOI link](https://www.probiotrial.org/) | 2019 |
| 55 | PRODOSE | Completed | N/A | BRAR | 228 | 2 | Continuous | Patients with cardiopulmonary bypass | Continuous (minutes) | Adaptive, open-label, randomised superiority trial. Early Stopping + RAR based on 1 interim analysis. Intervention: Drug. Control: Drug. | [Link](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003658) | 2021 |
| 56 | PROSpect / NCT03896763 | Recruiting | III | BRAR | 600 | 4 | Continuous | Respiratory | Ventilator-free days | | [DOI link](https://doi.org/10.1097/PCC.0000000000003541) | 2019 |
| 57 | RACE | completed | II | BRAR | 250 | 4 | Discrete | Septic Shock | Sequential organ failure assessment score at 48 hours from enrolment | | [DOI link](https://doi.org/10.1001/jamanetworkopen.2018.6076) | 2018 |
| 58 | REMAP-CAP / NCT02735707 | recruiting | III | BRAR | flexible | 16 domains, 56 arms in total | Binary | | 90-day mortality | | [DOI link](https://doi.org/10.1513/AnnalsATS.202003-192SD) | 2020 |
| 59 | REMAP-ECMO / NCT05913622 | Recruiting | N/A | BRAR | 430 | Ongoing platform | Binary | Cardiogenic shock | Proportion of patients successfully weaned from VA ECMO at 30 days | | [DOI link](https://doi.org/10.1016/j.ahj.2024.10.010) | 2023 |
| 60 | Restart tICrH / NCT04229758 | Not yet recruiting | III | BRAR | 1100 | 3 | Binary | Hemorrhage | Composite of thrombotic events | | [DOI link](https://clinicaltrials.gov/study/NCT04229758) | 2021 |
| 61 | SAFER / ISRCTN96528723 | Suspended | N/A | BRAR | Maximum size: 3.000 | 4 | Binary | Parents/guardians of children who test positive at screening (visual impairment) and are referred on to clinic in the Pono Yame MoH/Peek Vision school screening programme in 2022. | Attendance at clinic on invited date | | [DOI link](https://doi.org/10.1186/s13063-022-06519-y) | 2022 |
| 62 | Safety of Enoxaparin vs. Dextran-70 | completed | - | PTW | 327 | 2 | Binary | patients undergoing digestive surgery | Excessive bleeding (composite) | | [DOI link](httpscolons://doi.org/10.3109/00365529309098302) | 1993 |
| 63 | SEPSIS-ACT / NCT02508649 | Terminated | II/III | BRAR | 868 | 5 | Time-to-event | Sepsis | Vasopressor and mechanical ventilator free days (PVFDs) | | [DOI link](https://doi.org/10.1001/jama.2019.14607) | 2015 |
| 64 | SHINE / NCT01369069 | completed | III | BRAR | 1151/1400 | 2 | | acute ischemic stroke patients | number of patients with a favourable modified Rankin scale | | [DOI link 1](https://doi.org/10.1111/ijs.12045), [DOI link 2](https://doi.org/10.1186/s13063-015-0574-8) | 2014, 2015 |
| 65 | SNAP / NCT05137119 | Recruiting | IV | BRAR | 7000 | Ongoing platform | Binary | Staphylococcus aureus bacteraemia | All-cause mortality at 90 days after platform entry | | [DOI link](https://www.snaptrial.com.au/) | 2022 |
| 66 | SPRINT | completed | II | BRAR | 176 | 6 | Discrete | painful lumbosacral radiculopathy | Change from baseline in the mean 24-hour average general pain intensity (AGPI) score | | [DOI link](https://doi.org/10.1097/j.pain.0000000000000983) | 2017 |
| 67 | START / NCT03021928 | Not yet recruiting | III | BRAR | 1500 | 4 | Binary | Stroke | Composite occurrence of an ischemic or hemorrhagic event within 30 days of the index stroke | | [DOI link](httpshttps://doi.org/10.1177/1747493019870651) | 2017 |
| 68 | STEP-STONE | Unknown | N/A | BRAR | 10000 | Ongoing platform | Binary | Stroke | Global disability level was observed at 90 days | | [DOI link](https://doi.org/10.1186/s13063-022-06664-4) | 2022 |
| 69 | STOP-Sepsis / NCT05758246 | Recruiting | II | BRAR | 220 | 3 | Continuous | Sepsis | Difference in the composite cardiovascular, respiratory, and renal sequential organ failure assessment | | [DOI link](https://doi.org/10.1186/s13063-024-08474-2) | 2023 |
| 70 | StratosPHere 2 | recruiting | II | BRAR | 40 | 3 | | Pulmonary arterial hypertension | Target engagement (individual changes in 8 genes from baseline to follow-up) | | [DOI link 1](https://doi.org/10.1186/s13063-024-08485-z) | 2024 |
| 71 | STURDY / NCT02166333 | terminated | II | BRAR | 688/1200 | 4 | Time-to-Event | | Time to first fall or death (whichever comes first) | vitamin D supplementation for fall prevention in older adults | [DOI link](https://doi.org/10.1016/j.cct.2018.08.004) | 2018 |
| 72 | SWITCH-1 / NCT03596762 | Completed | II | BRAR | 199 | 5 | Continuous & ordinal | Vasomotor symptoms | Change From baseline in mean daily frequency of moderate and severe hot flushes from baseline to week 4 | | [DOI link](https://clinicaltrials.gov/study/NCT03596762?tab=results) | 2018 |
| 73 | tobacco cessation | completed | III | BRAR | 739 | 2 | Binary | Smoking | Biochemically verified abstinence | | [DOI link 1](https://doi.org/10.1186/s13063-017-2119-9), [DOI link 2](https://doi.org/10.1001/jamainternmed.2022.7170) | 2017, 2023 |
| 74 | Vibe Up / ACTRN12621001092886 | Not yet recruiting | N/A | Multi-arm bandit | 1200 | 4 | Continuous | Psychological distress | Self-reported psychological distress as measured by Depression Anxiety and Stress Scale - 21 item version (DASS-21) | | [DOI link](https://doi.org/10.1136/bmjopen-2022-066249) | 2021 |
| 75 | PREDICATE / NCT06472219 | Study Start (Actual) 2024-12-23 | 3 | Adaptive Platform Design and Response Adaptive Randomisation | 1300 | 2 | Binary | Respiratory Tract Infectionss | The proportion of patients with all-cause sepsis or all-cause mortality / The proportion of patients with an SAE| | N/A | N/A |
| 76 | PREVAIL / ORP-101 in patients with IBS-D / NCT04129619 | Completed | 2 | RAR sequential assignment study | 321 | 3 | Binary | Respiratory Tract Infections | Percentage of Participants Who Are Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores [Time Frame: Week 12] | | N/A | N/A |
| 77 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia |  Completed | II | Bayesian continuous reassessment method | 51 | 4 | Binary | AML/MDS | Combination of primary binary outcome with binary secondary outcomes |  | [DOI link 1] (https://doi.org/10.1016/j.bbmt.2010.09.022)| 2010 |
| 78 | Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma | Terminated | I/II | Bayesian adaptive randomization | 13 (phase I) + 5 (phase II) | 2 | Time-to-event | GBM | PFS |  | From ClinicalTrials.gov - https://clinicaltrials.gov/study/NCT01110876 | Last Update Posted: 2021-08-25 |
| 79 | BTTC-1102 - Phase I/​II Adaptive Randomized Trial of Bevacizumab vs. Bevacizumab + Vorinostat in Adults With Recurrent Glioblastoma | Completed | I/II | Bayesian adaptive randomization | 96 | 2 | Time-to-event | Glioblastoma | PFS |  | From ClinicalTrials.gov - https://clinicaltrials.gov/study/NCT01266031, [DOI link 1](https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.2012) | Last Update Posted: 2018-07-31 |

